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The accurac\' and precision of an intelligent dosing system (IDS) for FK506 in predicting 
doses to achieve target drug levels has been prospectively evaluated in transplant and 
autoimmune pallents. For dose individualization. the knowledge base is updated with 
patient·specH;c feedback including the current dose. drug le\'el. und the new larget level. 
The studv populatIon of 147 patients consIsted of 97 transplant pata:nts /lil'er and kid-
neYI and 50 patients IVlth autoimmune disorders. Patients In the transplant studv group 
were entered sequentiallv and followed as a cohort. Patients in the autoimmune study 
group were randoml~D assIgned to one of three predefined FK506 concentration Windows 
(low. 0.1-.3; medium. O.-l-.i; and high. 0.8-1.3 ng/mLI as part of a concentration con-
trolled clinical trial. Predictions of steady-state plasma drug lel'e/s were made throughout 
the clinical course of autoim mune patients and during the first /j weeks post-transplant in 
liver and kidney recipients. FK506 concentration in plasma was measured b,' a monoclo-
nal antibod\' based ELISA assav. Accuraq' was computed as the mean prediction error 
(mpel. Precision \\'as computed as the root mean squared prediction error Irmspel. The 
accuracv 0; the IDS in each studv group was as tallows: 0.016 ng;mL (liverl. -0.034 
ng/mL fkidne~DfI and -0.022 ng/mL (autoimmunel. Because the 95% confidence Interval 
included zero in each case. the IDS showed no bias. The preCIsion of the IDS in each studv 
group IVas as t'ol/O\\'s: 0.133 ng mL (/h·erl. 0.1903 ng/mL {kidnev!. and 0.11B8 ng;mL 
(autoImmune). These results indicate that the FK506IDS is both accurate and ,'en' precise 
(reproduciblel in transplant and autoimmune patients. The performance at the FK506 
compares ;al'Orabh' \\'Ith previous/v reported pharmacokilleUc doslIlg methods such as 
population nomo~rams and adaptive control teedback methods ileast-squares and Ba\'e-
sian;. Based on our "ndings. this IDS should have a number at Important uses relevant to 
the drug development process. the prescrIbing phYSIcian Clnd the Individual patient. It 
provides an effJcienl method for implementing concentratIOn controlled c1inicaJtrials. It 
should accelerate (he phvslclan's learning curve while a/the same tIme help to maXImize 
therapeutic drug effJcac,! and minimize toxicit~Dlvlth drugs exhibiting nonlinear kinetics 
and narrolV therapeutic indices. mreliminar~D studies suggest that these assets result in a 
signiftcant cost-benerit advantage by redUCing the duratIon of hospitalization. Current 
studies are III progress to validate this and care/uUv measure its pharmacoeconomic 
impact. 
FKS06 is a novel and promising new immunosuppres-
sive (lMS) agent currently under active clinical in-
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vestigation for the prevenllon and control of organ 
rejection and the treatment of autoimmune dis-
orders. I Preclinical studies in anlmal models and ini-
tial clinical experience suggested that FK506 has a 
narrow therapeutic index. large interpatient pharma-
cOKinetic (PKl variability with apparent dose-depen-
dent kinetics. and plasma level-related systemic tox-
icities. ~Kg Results from recent randomized and 
nonrandomlzcd clinical trials further confirm. that 
similar to cyclosporine A (CyAj. careful control and 
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monitoring of plasma (blood) drug levels of FKS06 are 
necessary to balance the opposing risks of over-im-
munosuppression such as drug-induced toxicity 
(e.g .. nephrotoxicity. infection. tumor) and under-
immunosuppression (e.g .. graft rejection).45 
Previous experience has shown that drug therapy 
and patient care can be improved by individualizing 
doses in drugs exhibiting a narrow therapeutic 
range. large PK variability. and a relationship be-
tween plasma drug levels and clinical pharmacody-
namic (PO) responses (therapeutic and adverse).6.7 
The optimal use of current immunosuppressive drug 
regimens (e.g .• CsA. Prednisone. Imuran) in the solid 
organ transplant patient requires the need to set ther-
apeutic goals by individualizing polydrug therapy as 
a function of patient status. i.e .. level of graft func-
tion. evidence of toxicity. rejection or graft-versus-
host disease and the current plasma CsA drug 
level. 8 .9 
Therefore. an accurate and simple-to-use dosing 
method that would predict doses and/or desired 
drug levels in individual patients and at the same 
time account for dynamic changes in physiologic sta-
tus should improve patient care by a) reducing sys-
temic drug-related toxicities. b) increasing the time 
spent in an effective nontoxic therapeutic range. and 
c) decreasing the length of hospitalization. all of 
which should result in a cost-benefit advantage. In a 
pilot study in solid-organ transplant recipients. we 
described our initial clinical experience with a novel 
IDS developed for FK506. IO The present study was 
undertaken to a) further evaluate the performance of 
this FK506 IDS in a larger sequential cohort of pa-
tients undergoing allogeneic liver and kidney trans-
plantation and b) compare its performance in a group 
of patients with autoimmune disorders who were 
randomly assigned to predefined FKS06 plasma con-
centration windows. 
MATERIALS AND METHODS 
The FK506 IDS used in this studv is a modified artifi-
cial intelligence program design~d to learn the dose-
level relationships for FK506 from dosing history and 
corresponding drug concentrations. The knowledge 
base for the IDS originally derived. consisted of 
steadv-state trough FK506 plasma levels in 142 adult 
heart. liver and kidney allograft recipients treated as 
both inpatients and outpatients at the University of 
Pittsburgh Presbyterian Medical Center under pri-
mary FK506 immunosuppressive therapy January 1. 
1990 to December 31. H190. IO 
To (Ibjectively assess the performance of the 
FKS06 iDS. a cohort studv was conducted at the Uni-
versity of Pittsburgh ;vledical Center. The entire 
study population (n = 147) consisted of a total of 50 
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adult liver and 47 adult kidney transplant recipients 
as well as 50 nontransplant patients with a variety of 
autoimmune disorders such as psoriasis. sclero-
derma. and rheumatoid arthritis. All treatment pro-
tocols were approved by the IRB of the University of 
Pittsburgh. Informed consent to use FK506 was ob-
tained in all patients enrolled in these studies. Clini-
cal studies were conducted under IND's 32463 
(transplantation). 34570 (psoriasis). 36317 (multiple 
sclerosis) 34548 (chronic active hepatitis and IND) 
34581 (primary biliary cirrhosis) monitored by the 
Food and Drug Administration. Rockville. Maryland. 
FK506 was provided by the Fujisawa Pharmaceuti-
cal Company of Japan. 
Patients in the autoimmune study group were ran-
domly assigned to one of three predefined FKS06 
concentration windows (0.1-0.3. 0.4-0.7. 0.8-1.3 ng/ 
mL as part of a concentration controlled clinical trial. 
The FK506 IDS was used to guide all doses to prospec-
tively achieve the target level specified in the proto-
col. Predictions of plasma drug levels were made 
throughout the clinical course of autoimmune pa-
tients and during the first 6 weeks of the post-trans-
plant course of transplant patients including both in-
travenous and oral doses of FK506. 
To be eligible for this cohort study. patients were 
required to have consecutive doses and correspond-
ing plasma levels obtained after achieving steady-
state. i.e .. at least 3 days of the current dose at regular 
intervals (e.g. every 12 hours) and at least 48 hours 
after administration of a new dose at regular inter-
vals. The time to steadv-state was also consistent 
with the average plasma terminal half-life of approxi-
mately 8-1S hours in these patients. lllz 
FK506 concentration in plasma was measured bv a 
monoclonal antibody based ELISA assay as previ-
ouslv described. I1 .12 The coefficient of variation ot' 
this assay is 1i% at 1.4 ng/mL: 14,4% at 2.9 ng/mL: 
and 12% at 5.7 ng/mL. The effective therapeutic 
range for FKS06 is estimated to be 0.5-2.0 ng/mL in 
transplant patients and is currently being defined in 
patients with autoimmune disorders. 
RESULTS 
The performance of the lOS was assessed using stan-
dard prediction error analysis. l ] The mean predic-
tion error (mpe). computed from the average devia-
tion between the observed and predicted target 
level. was used to describe accuracv or bias. The root 
mean squared prediction error (rmspe). computed as 
the standard deviation of the prediction error was 
used to describe precision. If the IDS were a perfect 
method. the mpe and the rmspe would be zero. The 
9S% confidence interval (CI) was calculated as the 
mean prediction error or the root mean squared pre-
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diction error plus or minus 1.96 times the SE. i.e .. TABLE II mpe + /- (1.96 X SE). 
Demographic characteristics of the patients in the Summary of Mean Prediction Error Analysis 
Standard 
TABLE I Deviation 01 Prediction 95% Confidence 
Summary of Demographic Data 
Patient Group mpe Error Limits 
-0.013 0.149 All groups 0.029--0.055 
Protocol All Sell Rae. Treatment Group Kidney transplant -0.034 0190 0.020--0.008 
AIED 36 Male White High Liver transplant 0.016 0.133 0.053--0.021 
AlS 57 Male White None Autoimmune diseases -0.022 0.119 0.011--0.055 
CAH·A 57 Female White High 
CAH·A 33 Female White Low 
CAH·A 28 Female White low 
autoimmune study group are summarized in Tablel. CAH·A 32 Female Other None 
CAH·A 34 Male White High The performance of the IDS in each of the study 
CAH·A 37 Female White Low groups and in the three groups combined is summa-
Diabetes 41 Male White High rized in Table II. In addition. the accuracy and preci-
ISO 31 Female White Low sion of the IDS in all study groups is shown in Figure IBO 48 Male White High 1. These graphs underscore the close correlation be-ISO 32 Female White None 
IBO 31 Male White High tween the observed and predicted levels. Despite the 
ISO 23 Female White High heterogeneity of the individual study groups and the 
MS 40 Female White Medium marked intersubject variability in kinetics. there are 
MS 41 Male White Low 
no significant outliers or individuals who are diffi-MS 56 Male White Medium 
MS 52 Male White Medium cult to predict. 
MS 46 Female White Medium The accuracy (mpe) of the IDS ranged from 0.016 
MS 37 Male White High (liver) to 0.034 (kidney) ng/mL. The accuracy of the 
MS 57 Female White Low combined study groups was 0.013 ng/mL. Because MS 48 Female White Low the 95% confidence interval in all groups includes MS 28 Female White High 
MS 39 Male White Medium zero. the IDS shows no bias in predicting FK506 lev-
MS 41 Male White High els in transplant and autoimmune patients. The pre-
MS 33 Female White Medium cision (rmspe) of the IDS ranged from 0.1188 (au-
MS 51 Female White Low toimmune) to 0.1903 (kidney). The rmspe in the MS 56 Female White Low 
MS 42 Female White High combined group was 0.1499 ng/mL. 
MS 37 Male White High To further put the performance of this IDS into 
Nephrotic 5 Male White Low perspective. a scattergram that depicts the observed 
Nephrotic 47 Male White Low relationship between a given dose and the corre-Nephrotic 10 Male White High 
sponding FK506 plasma level at steady-state for the Nephrotic 13 Male White Low 
Nephrotic 14 Male White Low combined study population is shown in Figure 2. The 
PSC 48 Female White Low FKS06 dose-level response profile is variable and 
PSC 65 Female White Low does not appear to be simply linear over the dose pec 49 Female White Low range of 0.S-60 mg/ day. Because FKS06 did not ex-PSC 51 Female White Low hibit dose proportionality with standard graphical PSC 32 Male White High 
PSC 53 Female White Low methods. 14 we explored the linearity versus nonlin-
PSC 27 Male White High earity of FKS06 by using a novel three-dimensional 
PSC 39 Female White Low graphical method recently described. IS PSC 41 Male White Low To help visualize and quantitate the apparent PSOriaSIS 52 Female Black High 
PsoriasIs 39 Male White Low dose-level relationship. we graphed three variables 
Pyoderma 56 Male White Low (current dose. new dose. and the associated percent 
Sclentls 24 Female White Low change in FKS06 level). The relationship between 
Sprue 39 Female White Low these parameters is shown in Figure 3. While there is VasculitiS 71 .Male White None 
relative linearity in the low dose range (> 10 mg/ 
A/EO· ,ulOlmmune mn'Ir ell' dlUase: ALS • a~lroplllC lal",", sclerOSIS: day), there is a rapid and disproportionate increase at CAH·A • autOImmune cllronlC IellVe lIepalltls: 180 • Inflammalory 00_ diS' higher total daily doses indicative of nonlinear phar-~rf: MS • mUIIlgl. sclerosIs: N.""rol/C • nepllrol/c synt1romft: PBC· pfllrta,., b,'Y,., c"rllOslS: PSC ... p"",.,., SClerosmg CIlO'-n/llllS; Low • 0.1-0.3 nlllmL: macokinetic behavior. 
M~· 04-0.7 "Il/mL: HlglI- 0.8-/.3 nlllmL: None· OaS/tO on mdlVldual The disproportionate increase in the surface area lUI,.,,' responsft. 
between a nonlinear plane and a linear plane can be 
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ci~ure I_ Scaltergrams 0; predicted versus observed FKSQ61eveis are shown for each studl' group In the com 01 ned ~roupI These graphs shOll 
the close correlation between the observed and predicted FKS06 plasma levels In ~lfch studl' group. The studv groups are as tol/@"S: 
a, ~idnevI liver, and autoimmune disease patients: b. ~idney transplant recIpients: c. Lin!r transplant reCIpients: d, Patients with au-
tOImmune diseases, 
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Fiqure 2. Scauerl!ram 01 the observed re/ollonshlp between FKS06 
dose o\'er a IVlde ran!!e 10_3-60 m~davD and the correspondin!! 
FKS06 plasma level lit steadl'·state In the combined studv populo· 
tlon. rhl! marked intersuo,ect \'arlabditv and the lacle of a stmp/e 
linear re/allonshlp t~ : 00J4' between FKS06 dose and achieved 
steadl'·state plasma le\'el IS e\'ldent, 
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seen in Figure 4. In this model. the degree at nonlin-
earitv is calculated as the nonlinear surface area di-
Vided bv the linear surface area, The surface area or' 
the nonlinear plane of fit was 1.88 times greater than 
a linear plane over the normal dosing range (0-50 
mg/day). This deviation from linearity especially at 
doses above 10 mg/day helps to explain why FK506 
doses should not be used alone to guide therapy 
without measuring druR levels as welL 
DISCUSSION 
We have prospectively evaluated the accuracy the 
precision of an IDS for FK506 in predicting doses to 
achieve target drug levels in transplant !liver. kid-
ney) and autoimmune patients. This IDS uses a 
knowledge-based derived from steady·state trough 
drug levels in transplant patients to learn (predict) 
the expected dose-level relationship for FK506. For 
dose individualization. the knowledge base is then 
updated with patient specific feedback. i.e .. current 
dose and drug level and the new target level. 
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ci~ure J ... \ three·dlmenslonol surtnce plot 01 the relatIonship be· 
tween current dose. nelV dose and the percent chanRe in FKS06 
level is depIcted. The sur/ace area o/Ihe nonlineor plane observed 
IVOS calculated usin,! Desl!!n C.-\D 3D. a so/Ilvare packaRe IVhich 
uses sur/ace Integrals to make the sur/ace area calcu/atian. 
We observed excellent predictive performance 
across all three groups studied. The accuracy (mpe) 
of the lOS was determmed to be -0.013 ng; mL in the 
combined study group. Since the 95% Cl includes 
lero. the lOS is without bias. The precision (rmspe) 
was determmed to be 0.1499 nSI mL in the combined 
study groups which represents less than 10% of the 
span of the effective therapeutic range (0.5-2.0 ngl 
mLI and less than the coefficient of vanation of the 
FK506 assay. Thus the IDS is both accurate and repro· 
ducible in transplant and autoimmune patients. The 
performance of the lOS in autoimmune patients. a 
cate~ory of patients excluded from the original 
ARTIFICIAL INTELLIGENCE ANO PHARMACOECONOMICS 
knowledge base. i.e .. transplant patients. is strong ev· 
idence of the broad applicability of artificial intelli· 
gence to the field of adaptive control dosing meth· 
ods. '6-'8 
The performance of the FK50610S in autoimmune 
patients compares favorably with previously reo 
ported PK guided methods such as population based 
nomograms and Bayesian prediction methods using 
feedback contro!' Because feedback methods (non· 
linear least-squares and Bayesian estimation) are 
usually more precise than population nomograms. 
our results were compared with feedback methods. 
For example. the follOWing performance results have 
been reported for digoxin: RMSE = 0.35. 0.36 and 
0.30 ng/mL: lidocaine: RMSE = 0.7. 0.55 and 0.9 
mcg/mL: theophylline: R\ISE = 2.3. 1.2 mcg/mL. 18 
In a prospective randomized concentration con-
trolled clinical trial of primarY FK506 prophylaxis in 
renal transplantation. wide intersubject variabilitv 
z 
I' ; 
JOS[ 
Fiqure -4 .• \ IhreeofJJmenslOnal pial at Ihe modeled relal1ons(lIp he-
fyyD~n Ihe fhn~ varIables fcurrenl dose. nelY dose and percenl 
,:hanl!e in FKS06 levell is sholVn. The uisproportronale Increase In 
the sur/urI' "rell f>elw~n nonlinear plane and u linear plane wllh 
IIICrf!usJnIl dUSI!S 01 FKS06 can ill! reat;.l\, Sf!en. 
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exists in PK parameters (e.g. clearance. bioavailabil-
ity), such that population or patient specific PK pa-
rameter values derh'ed from pre-transplant or post-
transplant PK profiles are not reliable in accurately 
predicting or achieving target steady-state drug lev-
els (Qais Mekki. personal communication). It seems 
unlikely .that these feedback methods can signifi-
cantly improve upon the performance achieved by 
the IDS especially given the nonlinearity in FKS06 
kinetics. 
This IDS has other important potential benefits be-
sides improved performance for achieving target lev-
els. Because this IDS requires no previous computer 
experience and is user friendly. it should help mini-
mize the learning curve and facilitate standardiza-
tion of care. This is especially true for the physician 
prescribing a drug like FKS06 for the first time with 
large PK variability and a narrow therapeutic index. 
Similar to the introduction of an effective new immu-
nosuppressive drug such as CsA with concurrent 
therapeutic drug monitoring in renal transplanta-
tion. the addition of FKS06 to the therapeutic arma-
mentarium coupled with this IDS should also trans-
late into a significant cost-benefit advantage. 19 Pre-
liminary studies at the University of Pittsburgh 
suggest that the cost of liver transplantation under 
FKS06 compared with CsA may be reduced by half 
or more due to shorter hospital stays (16.1 vs. 3S.9 
days).zo 
The IDS also offers potential benefits to the new 
drug development process. In the case of new drugs 
for disorders such as AIDS. cancer: or acute refrac-
tory organ rejection. it may not be feasible to do stan-
dard intense PK sampling earlv in drug development 
to estimate the PK pronle. dose proportionality and 
bioavailabilitv. As we have shown. the IDS com-
bined with th-e 3D graphic method requires only sin-
gle steady-state plasma samples for each dose level 
analyzed. PK-PD analysis using only trough levels 
should be informative since stead v-state FKS06 
trough levels closely correlate with the area under 
the curve. Therefore it should be possible to extract 
information from observational databases to esti-
mate the response surface of a new drug and assess 
its linearity or nonlinearity. This 3D graphic method 
should also be capable of estimating the change that 
occurs in the surface area of the plane when there is 
a drug-drug interaction. 
Finallv. this IDS is user friendlv and intuitive. It 
has been routinely used by transplant physicians 
without prior computer training or experience. To 
run the program. the physician is simply asked to 
make choices from menus to answer questions about 
a patient's condition that are relevant to anv trans-
plant patient receiving immunosuppressive drugs. 
For example. if a patient exhibits signs of drug toxic-
604 • J elln Pharmlcol 1993:33:599-605 
ity (nephrotoxicity) and has no evidence of rejection. 
then a reduction in FKS06 dosage is indicated. How-
ever. the physician must choose the new target drug 
level based on the current FK506 level and renal 
function. The only keyboard input required is to 
enter current FK506 doses and levels and the new 
target level. The IDS predicts the recommended dose 
based on the patient's previous dose-level historv. 
The IDS can also be used to predict the next FK506 
level given the current dose. current level and the 
new FKS06 dose. In short. dosing recommendations 
and adjustments are tailored to the individual pa-
tient. 
[n conclusion. the experience gained with this IDS 
in several hundred transplant patients and more re-
cently in autoimmune patients indicate that an in-
telligent PC based. user friendly dosing system can 
efficiently optimize FKs06 therapy. It also provides a 
practical and cost effective method for implementing 
concentration controlled clinical trials. Further-
more. it is probable that patients can learn to use this 
program as well and become more active partici-
pants in clinical decision making in a manner analo-
gous to patient-controlled analgesia. Through main-
tenance of safe and effective therapeutic drug levels 
which can be tailored to the individual patient. this 
IDS should result in even greater reductions in 
health care costs by reducing the likelihood of drug-
limiting toxicity while improving the likelihood of 
remaining free from rejection and therefore reduc-
ing the duration of hospitalization.!O Current studies 
are underway to validate this and more precisely 
measure its pharmacoeconomic impact. 
The authors thank :>.Is. Sandi :>.Iitchell and Lisa Lunl! tor expert 
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